AbbVie(US:ABBV) Financial Modeling Prep·2026-02-05 02:06Core Viewpoint - AbbVie Inc. is a leading biopharmaceutical company with strong financial performance in Q4 2025, driven by its immunology portfolio, and is projected to exceed profit expectations for 2026 [1][2][6] Financial Performance - AbbVie reported Q4 2025 sales of $16.62 billion, exceeding the consensus estimate of $16.42 billion, marking a 10% increase on a reported basis and a 9.5% increase operationally [2] - Adjusted earnings per share rose by 25.5% to $2.71, surpassing the expected $2.65 [2] Revenue Breakdown - The immunology portfolio generated global net revenues of $8.63 billion, reflecting an 18.3% increase, with Skyrizi sales up 32.5% to $5.01 billion and Rinvoq sales rising 29.5% to $2.37 billion [3] - Neuroscience sales climbed to $2.96 billion, a 17.9% increase, with Vraylar contributing $1.02 billion (up 10.5%) and Botox Therapeutics at $991 million (up 13.4%) [4] - The oncology portfolio saw a slight decline, generating $1.66 billion in sales, with Imbruvica's revenues down 20.8% to $671 million, while Venclexta's revenues increased by 8.6% to $711 million [4] Future Projections - AbbVie projects its 2026 profit to surpass Wall Street estimates, driven by strong sales of Skyrizi and Rinvoq [5][6] - The current stock price of ABBV is $216.97, reflecting a decrease of 3.85% or $8.69, with a market capitalization of approximately $383.47 billion [5]